Nurix Therapeutics offers a cash-backed, clinically leveraged bet on bexobrutideg becoming the first breakthrough BTK degrader, with Roche materially lowering funding risk ahead of pivotal data.
Overview
Nurix Therapeutics is a clinical-stage targeted protein degradation company whose investment case rests on a differentiated degrader platform and an increasingly de-risked lead asset, bexobrutideg. **The key inflection is the June 2026 Roche alliance, which brought in a $700.0 million upfront payment and lifted pro forma cash to approximately $1.24 billion, sharply reducing financing risk.** Nurix’s model blends internal pipeline value creation with strategic partnerships that validate its science and subsidize development. Its lead program, bexobrutideg, is the first BTK degrader to enter Phase 3, targeting relapsed/refractory CLL while also expanding into immunology and inflammation. Clinical data presented at EHA 2026 showed robust response rates across multiple CLL cohorts, including 83.0% ORR in Phase 1a and 92.9% ORR in a prior BTKi, BCL2i-naïve Phase 1b cohort. **The central debate is whether bexobrutideg can prove superiority versus pirtobrutinib in the planned DAYBreak CLL-306 study and become the standard of care in the post-covalent BTKi setting.** At $24.04 per share on July 6, 2026, the stock appeared supported by cash, platform optionality, and a consensus target of $32.20, while upcoming catalysts include Phase 3 initiation, I&I IND activity, and partnered pipeline updates.